SRZN trades 109.7% below Wall Street's consensus target of $54.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SRZN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 23, 2026, Surrozen, Inc. (SRZN) has a Wall Street consensus price target of $54.00, based on estimates from 6 covering analysts. With the stock currently trading at $25.75, this represents a potential upside of +109.7%. The company has a market capitalization of $193M.
Analyst price targets range from a low of $54.00 to a high of $54.00, representing a 0% spread in expectations. The median target of $54.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SRZN trades at a trailing P/E of -0.8x. Analysts expect EPS to grow +51.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $2.4B | $19.36 | $40.00 | +106.6% | Buy | — | 18 |
 ARQTArcutis Biotherapeutics, Inc. | $4.0B | $32.20 | $40.75 | +26.6% | Buy | 65.5x | 12 |
 IMVTImmunovant, Inc. | $6.0B | $29.10 | $40.00 | +37.5% | Buy | — | 23 |
 KYMRKymera Therapeutics, Inc. | $9.1B | $110.85 | $138.20 | +24.7% | Buy | — | 27 |
 PRTAProthena Corporation plc | $432M | $8.25 | $30.00 | +263.6% | Buy | 69.6x | 28 |
 REGNRegeneron Pharmaceuticals, Inc. | $84.4B | $819.09 | $856.25 | +4.5% | Buy | 14.0x | 49 |
 VRTXVertex Pharmaceuticals Incorporated | $135.8B | $535.17 | $573.50 | +7.2% | Buy | 28.6x | 56 |
 ALNYAlnylam Pharmaceuticals, Inc. | $30.3B | $227.28 | $347.23 | +52.8% | Buy | 34.3x | 52 |
 INCYIncyte Corporation | $23.7B | $116.93 | $134.40 | +14.9% | Buy | 35.7x | 44 |
 HALOHalozyme Therapeutics, Inc. | $14.8B | $124.54 | $110.00 | -11.7% | Buy | 14.5x | 27 |
Quick answers to the most common questions about buying SRZN stock.
The consensus Wall Street price target for SRZN is $54, representing 109.7% upside from the current price of $25.75. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SRZN has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $54 implies 109.7% upside from current levels.
SRZN's current price is $25.75 with a consensus target of $54 (109.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $54 for SRZN, while the most conservative target is $54. The consensus of $54 represents the median expectation. These targets typically reflect 12-month expectations.
SRZN is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SRZN stock forecast based on 6 Wall Street analysts shows a consensus price target of $54, with estimates ranging from $54 (bear case) to $54 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SRZN, with a "Buy" consensus rating and $54 price target (109.7% upside). 4 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SRZN analyst price targets range from $54 to $54, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $54 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.